Global Pharma Companies Must Nurture ‘Intercultural Intelligence’
Insights From Jesse Sibarium, SVP, General Manager At PTC Therapeutics
Equality, Diversity and Inclusion (ED&I) carries huge potential for business and society. However, various events around the globe, including the Black Lives Matter movement, highlighted that there are unaddressed challenges which need to be tackled. PTC Therapeutics, a global biopharmaceutical company with presence in in Europe, Middle East and Africa (EMEA) has initiated a new ED&I program to further strengthen its values and encourage positive progress globally.
• Source: Shutterstock
PTC Therapeutics, Inc. has been operating across more than 20 EMEA countries, arguably one of the most culturally diverse regions with over 2,000 languages spoken and every world religion represented, for nearly 10 years.
About the Author
Jesse Sibarium is senior vice president, general manager for Central Eastern Europe, Commonwealth of Independent States, Middle East and Africa at PTC Therapeutics.
PTC Therapeutics is a global biopharmaceutical company focused on the discovery, development and commercialization of medicines that provide benefits to patients with rare disorders.
The process of manufacturing medicines can often be complex, expensive and harmful to the environment. Initiatives like RESILIENCE UK are seeking to simplify this process, utilizing VR technology to create a more sustainable learning environment for both students and companies.
Despite the significant presence of East Asian professionals in the pharmaceutical industry, their representation in top leadership roles remains disproportionately low. This disparity can be attributed to cultural bias, limited access to influential networks, and systemic barriers within corporate structures.
Looking at a recent McKinsey report alongside our Evaluate data, the below infographic provides insight into the investment scene of pharma and raises questions as to how the industry is seemingly yet to seize the opportunity in women's health.
Despite significant investments in weight loss treatments, pharmaceutical companies face criticism for neglecting to study their drugs in obese patients, possibly leading to incomplete labeling and patient risks, prompting calls for the FDA to enforce more inclusive clinical trials and updated drug information.
